An oral vaccine based on U-Omp19 induces protection against B. abortus mucosal challenge by inducing an adaptive IL-17 immune response in mice

• Published in: PloS one 2011-01, Vol.6 (1), p.e16203-e16203
• Main Authors: Pasquevich, Karina A, Ibañez, Andrés E, Coria, Lorena M, García Samartino, Clara, Estein, Silvia M, Zwerdling, Astrid, Barrionuevo, Paula, Oliveira, Fernanda S, Seither, Christine, Warzecha, Heribert, Oliveira, Sergio C, Giambartolomei, Guillermo H, Cassataro, Juliana
• Format: Article
• Language: English
• Subjects: Adaptive Immunity; Adjuvants; Animal vaccines; Animals; Antigens, Bacterial - therapeutic use; Bacteria; Bacterial Outer Membrane Proteins - therapeutic use; Biochemistry; Biology; Bordetella pertussis; Brucella; Brucella abortus; Brucella abortus - immunology; Brucella Vaccine - administration & dosage; Brucella Vaccine - immunology; Brucellosis; Brucellosis - prevention & control; Candida albicans; CD4 antigen; CD4-Positive T-Lymphocytes - immunology; Contamination; Cytokines; Dendritic cells; E coli; Escherichia coli; Formulations; Genetic engineering; Genetically modified plants; Health aspects; Helper cells; Immune response; Immune system; Immunity; Immunization; Immunology; In vivo methods and tests; Infection; Infections; Interleukin 17; Interleukin-17 - immunology; Leaves; Lipoproteins - therapeutic use; Lymphocytes; Lymphocytes T; Medical research; Membrane proteins; Mice; Mucosal immunity; Neutralization; Oral administration; Outer membrane proteins; Pseudomonas aeruginosa; Salmonella; Salmonella Typhimurium; Staphylococcus aureus; T cells; Th1 Cells - immunology; Th17 Cells - immunology; TLR4 protein; Toll-like receptors; Transgenic mice; Transgenic plants; Tuberculosis; Vaccination; Vaccines; Whooping cough
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0016203

As Brucella infections occur mainly through mucosal surfaces, the development of mucosal administered vaccines could be radical for the control of brucellosis. In this work we evaluated the potential of Brucella abortus 19 kDa outer membrane protein (U-Omp19) as an edible subunit vaccine against brucellosis. We investigated the protective immune response elicited against oral B. abortus infection after vaccination of mice with leaves from transgenic plants expressing U-Omp19; or with plant-made or E. coli-made purified U-Omp19. All tested U-Omp19 formulations induced protection against Brucella when orally administered without the need of adjuvants. U-Omp19 also induced protection against a systemic challenge when parenterally administered. This built-in adjuvant ability of U-Omp19 was independent of TLR4 and could be explained at least in part by its capability to activate dendritic cells in vivo. While unadjuvanted U-Omp19 intraperitoneally administered induced a specific Th1 response, following U-Omp19 oral delivery a mixed specific Th1-Th17 response was induced. Depletion of CD4(+) T cells in mice orally vaccinated with U-Omp19 resulted in a loss of the elicited protection, indicating that this cell type mediates immune protection. The role of IL-17 against Brucella infection has never been explored. In this study, we determined that if IL-17A was neutralized in vivo during the challenge period, the mucosal U-Omp19 vaccine did not confer mucosal protection. On the contrary, IL-17A neutralization during the infection did not influence at all the subsistence and growth of this bacterium in PBS-immunized mice. All together, our results indicate that an oral unadjuvanted vaccine based on U-Omp19 induces protection against a mucosal challenge with Brucella abortus by inducing an adaptive IL-17 immune response. They also indicate different and important new aspects i) IL-17 does not contribute to reduce the bacterial burden in non vaccinated mice and ii) IL-17 plays a central role in vaccine mediated anti-Brucella mucosal immunity.